Abstract:Abstract Background Clinical interpretation of genetic variants in the context of the patient’s phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases. Artificial intelligence (AI) holds promise to greatly simplify and speed genome interpretation by integrating predictive methods with the growing knowledge of genetic disease. Here we assess the diagnostic performance of Fabric GEM, a new, AI-based, clinical decision support tool for expediting genome interpretation. Methods We benchmarked GEM in a retrospective cohort of 119 probands, mostly NICU infants, diagnosed with rare genetic diseases, who received whole-genome or whole-exome sequencing (WGS, WES). We replicated our analyses in a separate cohort of 60 cases collected from five academic medical centers. For comparison, we also analyzed these cases with current state-of-the-art variant prioritization tools. Included in the comparisons were trio, duo, and singleton cases. Variants underpinning diagnoses spanned diverse modes of inheritance and types, including structural variants (SVs). Patient phenotypes were extracted from clinical notes by two means: manually and using an automated clinical natural language processing (CNLP) tool. Finally, 14 previously unsolved cases were reanalyzed. Results GEM ranked over 90% of the causal genes among the top or second candidate and prioritized for review a median of 3 candidate genes per case, using either manually curated or CNLP-derived phenotype descriptions. Ranking of trios and duos was unchanged when analyzed as singletons. In 17 of 20 cases with diagnostic SVs, GEM identified the causal SVs as the top candidate and in 19/20 within the top five, irrespective of whether SV calls were provided or inferred ab initio by GEM using its own internal SV detection algorithm. GEM showed similar performance in absence of parental genotypes. Analysis of 14 previously unsolved cases resulted in a novel finding for one case, candidates ultimately not advanced upon manual review for 3 cases, and no new findings for 10 cases. Conclusions GEM enabled diagnostic interpretation inclusive of all variant types through automated nomination of a very short list of candidate genes and disorders for final review and reporting. In combination with deep phenotyping by CNLP, GEM enables substantial automation of genetic disease diagnosis, potentially decreasing cost and expediting case review.

Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data

Reanalysis of genomic data in rare disease: current practice and attitudes among Australian clinical and laboratory genetics services

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Evaluation of an Automated Genome Interpretation Model for Rare Disease Routinely Used in a Clinical Genetic Lab

New Developments and Possibilities in Reanalysis and Reinterpretation of Whole Exome Sequencing Datasets for Unsolved Rare Diseases Using Machine Learning Approaches

Unveiling the hidden: revisiting the potential of old genetic data for rare disease research

Increased Diagnostic Yield by Reanalysis of Whole Exome Sequencing Data in Mitochondrial Disease

Increase in Diagnostic Yield Achieved for 174 Whole-Exome Sequencing Cases Reanalyzed 1-2 Years after Initial Analysis.

Evaluation of an Automated Genome Interpretation Model for Rare Disease Routinely Used in a Clinical Genetic Laboratory.

Genome Sequencing reveals the impact of non-canonical exon inclusions in rare genetic disease

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases

Reanalysis of genomic data, how do we do it now and what if we automate it? A qualitative study

Beyond the exome: what's next in diagnostic testing for Mendelian conditions

Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection

Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases

Structural variant calling and clinical interpretation in 6224 unsolved rare disease exomes

The current landscape of clinical exome and genome reanalysis in the U.S.

Lessons learned from rapid exome sequencing for 575 critically ill patients across the broad spectrum of rare disease

Genome Sequencing for Diagnosing Rare Diseases

REVEL: an Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants